Welcome to our dedicated page for Ernexa Therapeutics SEC filings (Ticker: ERNAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ernexa Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ernexa Therapeutics's regulatory disclosures and financial reporting.
Ernexa Therapeutics Inc. (ERNA) reported that director James Arthur Bristol received two grants of stock options to purchase common stock. On 2026-08-31, he was granted 8,320 options with a $4.57 exercise price, expiring on 2036-08-31, vesting one-third on the first anniversary and the remainder in 24 monthly installments, subject to continued service. He was also granted 5,083 options at a $4.57 exercise price, expiring on 2036-08-31, in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, with 100% vesting on December 31, 2026, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that director Peter Cicala received two grants of stock options on August 31, 2026. One grant covers 5,943 options with an exercise price of $4.57 per share, vesting one-third on the first anniversary and the rest in 24 monthly installments, expiring August 31, 2036. A second grant covers 5,083 options at $4.57 per share, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vesting 100% on December 31, 2026, also expiring August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that director David Polinsky received a grant of stock options covering 5,083 shares of common stock. The options have an exercise price of $4.57 per share, were granted in lieu of prorated director cash compensation for 2026 under the company’s 2026 Omnibus Equity Incentive Plan, and expire on August 31, 2036. Subject to continued service, 100% of the options vest on December 31, 2026, and Polinsky’s total holdings of this option grant are 5,083 options following the reported transaction.
Ernexa Therapeutics Inc. (ERNA) reported that director William A. Wexler received a grant of stock options for 5,943 shares of common stock. The options have an exercise price of $4.57 per share and expire on August 31, 2036. Following this grant, Wexler holds 5,943 stock options directly. Vesting is time-based: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that President and CEO Luther Sanjeev received a grant of stock options. The award covers 118,848 options to acquire Ernexa common shares at an exercise price of $4.57 per share, expiring on 2036-08-31. Following this grant, Sanjeev holds 118,848 derivative securities of this type.
The options vest over time: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc., a pre-clinical iMSC cell-therapy company, reported a six-month net loss of $9.5 million to June 30, 2026, driven by $4.7 million in research and development as it advances lead oncology candidate ERNA‑101 and autoimmune program ERNA‑201. General and administrative expense was $2.9 million and a $2.0 million goodwill impairment eliminated all goodwill.
Cash was approximately $5.0 million at June 30, 2026 and about $7.4 million by August 4, after a February public offering delivering $9.5 million in net proceeds and subsequent ATM sales of 461,851 shares for $3.7 million. Management notes this cash is below forecast needs for the next 12 months and plans to rely on remaining ATM capacity under a $50.0 million shelf. During the quarter Ernexa completed a 1‑for‑25 reverse stock split to regain Nasdaq bid‑price compliance and recognized a $41,000 gain from extinguished contingent consideration. An independently run preclinical study in July 2026 reproduced ERNA‑101’s complete tumor clearance and durable survival in ovarian cancer models, supporting an IND filing planned for 2026 and a first‑in‑human Phase 1 trial thereafter.
Ernexa Therapeutics Inc. furnished an updated investor presentation as part of a current report on Form 8-K. The July 2026 presentation, attached as Exhibit 99.1, updates materials first posted in February 2026 and will also be available on the company’s investor relations website.
The company states that it routinely uses its website to distribute important information, including press releases, investor presentations and financial data, and offers email alerts when new materials are posted. The information in this item and Exhibit 99.1 is being provided as “furnished,” not “filed,” under the Exchange Act.
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the May 6, 2026 record date, there were 1,166,333 common shares outstanding, and 619,741 shares, or about 53.13%, were represented, establishing a quorum.
Stockholders elected five directors to serve until the 2027 annual meeting, ratified Haskell & White LLP as independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. No other matters were brought to a vote.
Ernexa Therapeutics Inc. announced that Senior Vice President of Finance Sandra Gurrola has submitted her resignation, effective July 3, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.
After her resignation becomes effective, Ms. Gurrola has agreed to provide transition assistance on a part-time basis for up to 10 hours per week through the filing of Ernexa’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa has begun a search for her successor and plans to use additional outside support to help with finance, accounting, and reporting until a replacement is appointed.
Ernexa Therapeutics Inc. received an amendment to a Schedule 13G filed by Clear Street LLC that terminates Clear Street's reporting obligation. The amendment states Clear Street's beneficial ownership is 0 shares, representing 0.0% of the common stock and therefore below the 5% reporting threshold.
The amendment explains no reporting obligation existed at the time of the original filing and is signed by John DiBacco, Head of Markets Trading on 05/20/2026.